HomeNewsScreenerChartsMapsGroupsPortfolioInsiderFuturesForexCryptoCalendarPricing
Theme 		Help
Open in Screener

ACTU

Actuate Therapeutics Inc

Last Close
Apr 02  •  04:00PM ET
2.48
Dollar change
-0.01
Percentage change
-0.40 %
Healthcare • Biotechnology • USA • NASD
Peers: JNJ LLY MRNA PFE MRK REGN BNTX GILD NVAX VIR
 | Held by: VTI IWM VXF IWO VTWO IWC VTWG RSSL URTY UWM
IndexRUT P/E- EPS (ttm)-1.08 Insider Own58.27% Shs Outstand23.25M Perf Week9.25%
Market Cap58.80M Forward P/E- EPS next Y-0.99 Insider Trans-1.99% Shs Float9.89M Perf Month-18.69%
Enterprise Value46.04M PEG- EPS next Q-0.20 Inst Own12.92% Short Float6.77% Perf Quarter-59.48%
Income-22.23M P/S- EPS this Y22.51% Inst Trans4.96% Short Ratio9.08 Perf Half Y-64.21%
Sales0.00M P/B7.28 EPS next Y-20.93% ROA-190.35% Short Interest0.67M Perf YTD-59.48%
Book/sh0.34 P/C4.47 EPS next 5Y-0.10% ROE-553.75% 52W High11.99 -79.32% Perf Year-64.11%
Cash/sh0.56 P/FCF- EPS past 3/5Y-0.08% - ROIC-266.87% 52W Low2.05 20.93% Perf 3Y-
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin- Volatility15.22% 12.81% Perf 5Y-
Dividend TTM- EV/Sales- EPS Y/Y TTM23.52% Oper. Margin- ATR (14)0.34 Perf 10Y-
Dividend Ex-Date- Quick Ratio2.39 Sales Y/Y TTM- Profit Margin- RSI (14)40.49 Recom1.00
Dividend Gr. 3/5Y- - Current Ratio2.39 EPS Q/Q40.64% SMA20-1.75% Beta0.87 Target Price17.75
Payout- Debt/Eq0.05 Sales Q/Q- SMA50-31.41% Rel Volume0.58 Prev Close2.49
Employees12 LT Debt/Eq0.05 EarningsFeb 25 SMA200-59.41% Avg Volume73.76K Price2.48
IPOAug 13, 2024 Option/ShortNo / Yes EPS/Sales Surpr.13.68% - Trades Volume42,815 Change-0.40%
Date Action Analyst Rating Change Price Target Change
Aug-26-25Initiated B. Riley Securities Buy $20
Apr-22-25Initiated Craig Hallum Buy $21
Mar-17-25Initiated H.C. Wainwright Buy $20
Mar-24-26 07:00AM
Actuate Therapeutics: Poised for Potential $200M+ Pediatric Priority Review Vouchers and Transformative Combinations in RAS-Driven Cancers
(ACCESSWIRE) -9.43%
Mar-09-26 08:45AM
Actuate Therapeutics Launches Strategic Research Initiative to Combine Elraglusib with RAS Inhibitors
(GlobeNewswire)
Mar-04-26 05:00PM
Actuate Therapeutics to Present at The Citizens Life Sciences Conference
(GlobeNewswire)
Feb-24-26 08:45AM
Actuate Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
(GlobeNewswire) +10.64%
Feb-06-26 01:58PM
Mettler-Toledo Q4 Earnings Top Estimates, Sales Rise Y/Y
(Zacks)
08:45AM Loading…
Jan-21-26 08:45AM
Actuate Therapeutics Announces Plans to Expand Clinical Pipeline, Advancing Elraglusib Tablet into a Phase 1/2 Clinical Program in Refractory Cancers
(GlobeNewswire) +5.40%
Jan-12-26 08:45AM
Actuate Therapeutics Reports Positive Follow-Up Data from its Randomized Controlled Phase 2 Trial Demonstrating Extended Long-Term Overall Survival Benefit with Elraglusib Plus Chemotherapy for Metastatic Pancreatic Cancer in Oral Presentation at ASCO GI 2026
(GlobeNewswire) -6.35%
Jan-06-26 08:45AM
Actuate Therapeutics Announces Positive Patient Outcomes from Phase 1 Trial in Difficult-to-Treat Refractory Pediatric Cancers
(GlobeNewswire) +5.05%
Dec-24-25 12:00PM
Actuate Therapeutics, Inc. (ACTU) Upgraded to Buy: What Does It Mean for the Stock?
(Zacks)
Dec-18-25 08:45AM
Actuate Therapeutics Phase 2 Metastatic Pancreatic Cancer Data Selected for Oral and Poster Presentation at ASCO GI 2026
(GlobeNewswire)
Dec-15-25 08:45AM
Actuate Therapeutics Announces Publication of Positive Phase II Clinical Data for Elraglusib Combined with Platinum Chemotherapy and Sequential Immunotherapy in Recurrent, Metastatic Salivary Gland Carcinoma
(GlobeNewswire) -8.78%
Nov-28-25 09:55AM
How Much Upside is Left in Actuate Therapeutics, Inc. (ACTU)? Wall Street Analysts Think 214.06%
(Zacks) +10.58%
Sep-22-25 08:45AM
Actuate Therapeutics Provides FDA with Updated Clinical Data Package to Support Planned Regulatory Interactions with FDA and EMA Over the Coming Months
(GlobeNewswire) +6.78%
Sep-11-25 04:01PM
Actuate Therapeutics Announces Closing of $17.25 Million Public Offering of Common Stock, Including Full Exercise of Over-Allotment Option
(GlobeNewswire)
Sep-10-25 08:31AM
Actuate Therapeutics Announces Pricing of $15.0 Million Public Offering of Common Stock
(GlobeNewswire) -19.15%
04:07PM Loading…
Sep-09-25 04:07PM
Actuate Therapeutics Announces Proposed Public Offering of Common Stock
(GlobeNewswire) +7.18%
Aug-06-25 08:45AM
Actuate Therapeutics To Collaborate with Incyte Corporation and the University of Pittsburgh on Clinical Trial of Elraglusib in Combination with Retifanlimab and mFOLFIRINOX in Patients with Advanced Pancreatic Cancer
(GlobeNewswire) +11.76%
Jul-17-25 08:45AM
Actuate Therapeutics Advances Clinical Program in Ewing Sarcoma After Positive Phase 1 Trial Demonstrates Complete and Partial Responses in Difficult-to-Treat Pediatric Sarcomas
(GlobeNewswire)
Jun-24-25 09:15AM
Actuate Therapeutics Highlights Significant and Sustained Survival Benefit in Key Metastatic Pancreatic Cancer Patient Populations in Phase 2 Elraglusib Trial
(GlobeNewswire)
Jun-20-25 08:45AM
Actuate Therapeutics Reports Positive Biomarker and Machine Learning Data from Phase 2 Elraglusib Trial in First-Line Treatment of Metastatic Pancreatic Cancer at ASCO
(GlobeNewswire)
Jun-16-25 08:30AM
Actuate Therapeutics Announces Inclusion in the Russell 3000 and Russell 2000 Indexes
(GlobeNewswire)
Jun-03-25 09:15AM
Actuate Therapeutics shares highlights from KOL eventon elraglusib data
(TipRanks) -7.93%
Jun-02-25 09:00AM
Actuate Therapeutics Shares Highlights from KOL Event on Positive Topline Elraglusib Phase 2 Data in First-Line Treatment of Metastatic Pancreatic Cancer
(GlobeNewswire) -11.01%
May-31-25 04:30PM
Actuate Therapeutics Presents Topline Elraglusib Phase 2 Data at ASCO 2025 Annual Meeting: Trial Meets Primary Endpoint of Median Overall Survival and Doubles 1-Year Survival in First-Line Treatment of Metastatic Pancreatic Cancer
(GlobeNewswire)
May-22-25 05:05PM
Actuate Therapeutics Announces Details for 2025 ASCO Annual Meeting Presentation on Topline Elraglusib Phase 2 Data in First-Line Treatment of Metastatic Pancreatic Cancer
(GlobeNewswire) -8.01%
May-07-25 08:00AM
Actuate Therapeutics to Host KOL Event on Topline Phase 2 Data of Elraglusib in Metastatic Pancreatic Ductal Adenocarcinoma During ASCO Annual Meeting
(GlobeNewswire)
May-06-25 08:00AM
Actuate Therapeutics Announces Statistically Significant Topline Results from Global Phase 2 Trial of Elraglusib in First-Line Treatment of Metastatic Pancreatic Cancer
(GlobeNewswire) -6.88%
Apr-30-25 08:00AM
Actuate Therapeutics to Participate in Citizens Life Sciences Conference 2025
(GlobeNewswire)
Apr-23-25 10:24AM
Actuate to Present Elraglusib Phase 2 Topline Data at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
(GlobeNewswire) +5.63%
Apr-17-25 08:00AM
Actuate to Present Promising Data on Elraglusib in Advanced Salivary Gland Carcinoma at the AACR Annual Meeting 2025
(GlobeNewswire)
04:01PM Loading…
Mar-27-25 04:01PM
Lantern Pharma Provides Business Updates and Fourth Quarter & Year-End 2024 Financial Results
(Business Wire) -5.25%
Mar-26-25 09:15AM
Actuate Therapeutics: Looking To Make An Impact In Pancreatic Cancer
(SeekingAlpha)
Feb-25-25 08:00AM
Actuate Announces Completion of Enrollment in a Phase 2 Trial of Elraglusib in Combination with FOLFIRINOX and Losartan in Patients with Previously Untreated Metastatic Pancreatic Cancer
(GlobeNewswire)
Feb-06-25 08:00AM
Actuate Therapeutics to Participate in Upcoming Investor Conferences in February
(GlobeNewswire) -6.56%
Jan-07-25 08:00AM
Actuate Therapeutics Receives EMA Orphan Medicinal Product Designation for Elraglusib for the Treatment of Pancreatic Cancer
(GlobeNewswire)
Dec-17-24 08:28AM
Actuate Therapeutics Announces Positive Interim Phase 2 Data of Elraglusib in First Line Treatment of Metastatic Pancreatic Cancer
(GlobeNewswire) -11.85%
Nov-26-24 08:00AM
Actuate Therapeutics to be Added to Russell 2000 Index
(GlobeNewswire)
Nov-12-24 08:00AM
Actuate Announces FDA Rare Pediatric Disease Designation Granted to Elraglusib for Treatment of Ewing Sarcoma
(GlobeNewswire)
Oct-29-24 06:39PM
Actuate to Participate in Lantern's Pharma Webinar on AI-Driven Drug Development
(GlobeNewswire)
Sep-23-24 08:00AM
Actuate Announces Scientific Reports Publication on Elraglusib's Novel Immunomodulatory Mechanism of Action as a GSK-3 Inhibitor
(GlobeNewswire) -8.89%
Sep-16-24 08:00AM
Actuate Announces Upcoming Presentation on Initial Data on Elraglusib in Combination with FOLFIRINOX at the AACR Special Conference on Advances in Pancreatic Cancer Research
(GlobeNewswire)
Sep-11-24 08:00AM
Actuate Receives FDA Orphan Drug Designation for Elraglusib for Treatment of Soft Tissue Sarcomas
(GlobeNewswire)
Sep-09-24 08:00AM
Actuate Therapeutics Obtains Complete Responses and Provides Update on Clinical Trial of Elraglusib for the Treatment of Relapsed/Refractory Ewing Sarcoma
(GlobeNewswire)
Sep-05-24 09:10AM
Actuate to Present at the H.C. Wainwright 26th Annual Global Investment Conference
(GlobeNewswire)
Aug-20-24 09:00AM
Actuate Therapeutics to Ring the Nasdaq Opening Bell on Friday, August 23, 2024
(GlobeNewswire)
Aug-14-24 04:05PM
Actuate Therapeutics Announces Closing of Initial Public Offering
(GlobeNewswire) +6.27%
Aug-12-24 08:27PM
Actuate Therapeutics Announces Pricing of Initial Public Offering
(GlobeNewswire)
May-28-24 07:00AM
Actuate Therapeutics Files Registration Statement for Initial Public Offering
(GlobeNewswire)
Actuate Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing therapeutics which target cancers and neurodegenerative diseases. It offers treatment for cancer and inflammatory diseases. It focuses on developing elraglusib. The company was founded by Andrew P. Mazar on January 16, 2015 and is headquartered in Fort Worth, TX.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SCHMITT DANIEL MPresident, CEO and DirectorFeb 13 '26Option Exercise0.00272,0550272,055Feb 13 06:10 PM
THOMSON TODD SDirectorJan 05 '26Sale5.80280,0001,624,000904,795Jan 07 12:45 PM
Kairos Venture Partners II, L.AffiliateDec 11 '25Proposed Sale7.60280,0002,128,000Dec 11 04:22 PM
Bios Equity COF, LPDirectorJun 27 '25Buy7.0071,428499,996196,428Jun 30 01:03 PM
Kreis Leslie W.DirectorJun 27 '25Buy7.0071,428499,996196,428Jun 30 01:02 PM
Fletcher Aaron G.L.DirectorJun 27 '25Buy7.0071,428499,996196,428Jun 30 01:01 PM
open in screener | open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
Open in Screener

LTRN

Lantern Pharma Inc

Last Close
Apr 02  •  04:00PM ET
1.62
Dollar change
+0.20
Percentage change
14.08 %
Healthcare • Biotechnology • USA • NASD
LTRN Lantern Pharma Inc daily Stock Chart
Peers: EXAI DNLI FATE IMTX KRYS RAPT RPTX XERS ARDX
 | Held by: VTI VXF MEDX IWC DFSU DFAC DCOR DXUV
Index- P/E- EPS (ttm)-1.57 Insider Own22.18% Shs Outstand11.25M Perf Week-22.49%
Market Cap18.23M Forward P/E- EPS next Y-2.02 Insider Trans0.00% Shs Float8.76M Perf Month-42.55%
Enterprise Value8.19M PEG- EPS next Q-0.36 Inst Own11.29% Short Float3.57% Perf Quarter-46.53%
Income-17.12M P/S- EPS this Y-10.83% Inst Trans0.09% Short Ratio0.64 Perf Half Y-60.68%
Sales0.00M P/B2.79 EPS next Y-16.09% ROA-93.52% Short Interest0.31M Perf YTD-46.53%
Book/sh0.58 P/C1.80 EPS next 5Y-10.36% ROE-123.51% 52W High5.74 -71.80% Perf Year-52.63%
Cash/sh0.90 P/FCF- EPS past 3/5Y-6.13% -10.59% ROIC-262.00% 52W Low1.11 45.95% Perf 3Y-66.46%
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin- Volatility49.91% 17.46% Perf 5Y-91.86%
Dividend TTM- EV/Sales- EPS Y/Y TTM18.69% Oper. Margin- ATR (14)0.32 Perf 10Y-
Dividend Ex-Date- Quick Ratio2.40 Sales Y/Y TTM- Profit Margin- RSI (14)35.05 Recom1.00
Dividend Gr. 3/5Y- - Current Ratio2.40 EPS Q/Q33.55% SMA20-24.10% Beta1.84 Target Price22.67
Payout- Debt/Eq0.01 Sales Q/Q- SMA50-37.42% Rel Volume2.64 Prev Close1.42
Employees16 LT Debt/Eq0.00 EarningsMar 30 AMC SMA200-54.19% Avg Volume489.98K Price1.62
IPOJun 11, 2020 Option/ShortYes / Yes EPS/Sales Surpr.21.74% - Trades Volume1,294,618 Change14.08%
Date Action Analyst Rating Change Price Target Change
Oct-07-21Initiated H.C. Wainwright Buy $32
Apr-02-26 09:00PM
Lantern Pharma Inc (LTRN) Q4 2025 Earnings Call Highlights: Strategic Advances Amid Financial ...
(GuruFocus.com) +14.08%
08:10AM
Lantern Pharma Invites Investors, Analysts & Shareholders to Experience the Future of Drug Discovery via a Live Demo of withZeta.ai the World's First Multi-Agentic Co-Scientist for Rare Cancers 8:30 AM Eastern, April 9, 2026
(Business Wire)
Mar-30-26 04:05PM
Lantern Pharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
(Business Wire) +10.27% +10.93%
Mar-27-26 07:29AM
Lantern Pharma and Starlight Therapeutics Announce FDA Clearance of IND for a Planned Phase 1 Pediatric CNS Cancer Trial of STAR-001
(Business Wire) -46.41%
Mar-23-26 04:30PM
Lantern Pharma to Report Fourth Quarter and Fiscal Year 2025 Operating & Financial Results on March 30th, 2026 at 4:30 p.m. ET
(Business Wire) +5.16%
11:19AM Loading…
Feb-12-26 11:19AM
Lantern Pharma (LTRN) Advances Oncology AI and Gains Orphan Drug Recognition
(Insider Monkey) -5.61%
Feb-10-26 08:45AM
Lantern Pharma to Present at the 7th Glioblastoma Drug Development Summit in Boston on February 17-19, 2026
(Business Wire) +7.38%
Jan-20-26 08:00AM
Lantern Pharma's LP-284 Receives FDA Orphan Drug Designation for Soft Tissue Sarcomas
(Business Wire)
Jan-12-26 09:00AM
Lantern Pharma Announces Establishing an A.I. Center of Excellence in India to Industrialize the RADR Platform and Accelerate Global Development Opportunities with BioPharma Companies
(Business Wire)
Dec-03-25 08:35AM
Lantern Pharma Reports Additional Positive LP-184 Phase 1a Results Showing Durable Disease Control in Heavily Pre-Treated Advanced Cancer Patients as Company Advances Precision Oncology Program into Multiple Biomarker-Guided Phase 1b/2 Trials
(Business Wire)
Nov-13-25 08:30AM
Lantern Pharma Reports Third Quarter 2025 Financial Results and Provides Business Updates
(Business Wire)
Nov-06-25 08:00AM
Lantern Pharma to Report Third Quarter 2025 Operating & Financial Results on November 13th, 2025 at 9:00 a.m. ET
(Business Wire) -5.35%
Oct-30-25 08:00AM
Lantern Pharma to Present AI-Driven Cancer Drug Development & Research Platforms at Inaugural AI for Biology and Medicine Symposium at UNT
(Business Wire)
Oct-28-25 08:49AM
Lantern Pharma Presents LP-284 Clinical Data at 25th LL&M Congress, Highlighting Complete Response in Therapeutically Exhausted DLBCL Patient & Therapeutic Potential in Advanced B-Cell Cancers.
(Business Wire)
Oct-24-25 08:00AM
Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 30, 2025
(Business Wire) +10.27%
08:29AM Loading…
Sep-16-25 08:29AM
Lantern Pharmas LP-184 Phase 1a Clinical Trial Achieves All Primary Endpoints with Robust Safety Profile and Promising Antitumor Activity in Multiple Advanced Solid Tumors
(Business Wire) +7.61%
Sep-03-25 09:44AM
Lantern Pharma Announces Completion of Type C Meeting with FDA, Providing Clarity on Regulatory Pathway for Pediatric CNS Cancer Trial
(Business Wire) +6.45%
Aug-13-25 04:30PM
Lantern Pharma Reports Second Quarter 2025 Financial Results and Business Updates
(Business Wire) +6.97%
Aug-07-25 05:34AM
FDA clears Starlight Therapeutics IND for Phase Ib/IIa glioblastoma trial
(Clinical Trials Arena)
Aug-06-25 08:30AM
Lantern Pharma's Subsidiary, Starlight Therapeutics, Announces U.S. Food and Drug Administration Clearance of IND for Phase Ib/2a Glioblastoma Multiforme (GBM) Trial
(Business Wire)
Aug-04-25 08:55AM
Lantern Pharma Announces Public Release of Transformative, Advanced AI Module for Blood-Brain Barrier Permeability Prediction, predictBBB.ai
(Business Wire) +11.53%
Aug-01-25 05:45AM
Lantern Pharma concludes patient enrolment for trial of LP-300 in Japan
(Clinical Trials Arena) +7.43%
Jul-31-25 07:30AM
Lantern Pharma Completes Targeted Enrollment for Lung Cancer Phase 2 Harmonic Clinical Trial in Japan for LP-300
(Business Wire) +10.72%
Jul-28-25 08:00AM
Lantern Pharma Announces Appointment of Dr. Lee Schalop to Board of Directors
(Business Wire) -5.31%
Jul-23-25 07:56AM
Lantern Pharma Reports Complete Response in Heavily Pre-Treated Lymphoma Patient with LP-284 in Phase 1 Clinical Trial
(Business Wire)
Jul-21-25 08:20AM
Lantern Pharma Secures EU Patent Allowance for LP-284, Bolstering Global IP Position for AI-Developed Cancer Therapy
(Business Wire) -5.01%
Jul-16-25 08:30AM
IBN Initiates Coverage of Lantern Pharma Inc.
(GlobeNewswire) +6.12%
Jul-15-25 09:40AM
Lantern Pharma Unveils Groundbreaking AI-Powered Module to Predict Activity and Efficacy of Combination Regimens in Clinical Cancer Treatment
(Business Wire) -5.76%
Jun-16-25 08:30AM
Lung Cancer Patient in Lantern Pharma's Harmonic Trial Shows Durable Complete Response in Target Cancer Lesions with Survival Continuing for Nearly Two Years
(Business Wire)
May-29-25 11:21PM
Lantern Pharma Inc. (LTRN)'s LP-184 Shows 345% Survival Gain in Rare Pediatric Brain Tumor Models
(Insider Monkey) +9.06%
08:30AM Loading…
08:30AM
Lantern Pharma's LP-184 Shows Promising In Vivo Activity in Atypical Teratoid Rhabdoid Tumors (ATRT) at SNO Pediatric Conference, Further Validating Rare Pediatric Disease Designation and Pathway to Clinical Trials
(Business Wire)
May-15-25 08:45AM
Lantern Pharma Reports First Quarter 2025 Financial Results and Business Updates
(Business Wire)
May-12-25 09:00AM
Lantern Pharma Secures FDA Clearance for Planned Phase 1b/2 Trial of LP-184 in Biomarker-Defined, Treatment-Resistant NSCLC Patients with High Unmet Clinical Need
(Business Wire)
08:31AM
EXCLUSIVE: FDA Clears Lantern Pharma's Planned Phase 1b/2 Trial of LP-184 In Treatment-Resistant Lung Cancer Patients
(Benzinga)
May-08-25 08:30AM
Lantern Pharma to Report First Quarter 2025 Operating & Financial Results on May 15th, 2025 at 9:00 a.m. ET
(Business Wire) -11.06%
May-05-25 08:55AM
Lantern Advances Drug Candidate LP-184 with IND Clearance for Phase 1b/2 Clinical Trial in Triple Negative Breast Cancer (TNBC)
(Business Wire)
08:31AM
EXCLUSIVE: Lantern Advances Breast Cancer Drug Candidate With FDA Clearance For Early-Stage Trial
(Benzinga)
Apr-01-25 09:01PM
Lantern Pharma Inc (LTRN) Q4 2024 Earnings Call Highlights: Navigating Growth and Challenges
(GuruFocus.com) -6.50%
Mar-27-25 08:35PM
Lantern Pharma Inc. (LTRN) Q4 2024 Earnings Call Transcript
(Seeking Alpha)
04:01PM
Lantern Pharma Provides Business Updates and Fourth Quarter & Year-End 2024 Financial Results
(Business Wire)
Mar-20-25 08:00AM
Lantern Pharma to Report Fourth Quarter and Fiscal Year 2024 Operating & Financial Results on March 27th, 2025 at 4:30 p.m. ET
(Business Wire)
Mar-12-25 06:00AM
How long-term energy plays outshine short-term hype
(Yahoo Finance Video) +7.56%
Feb-20-25 04:14PM
Lantern Pharma (LTRN) Files Patent for AI-Powered Blood-Brain Barrier Prediction Tech
(Insider Monkey) -6.68%
Feb-19-25 08:00AM
Lantern Pharma Announces PCT Patent Application Publication for Innovative, High Performing, Machine Learning Model for Predicting Blood Brain Barrier Permeability of Drug-Candidates
(Business Wire)
Jan-27-25 06:54PM
Lantern Pharma Inc. (LTRN) Enhances RADR® AI Platform to Accelerate Development of Antibody-Drug Conjugates (ADCs) for Targeted Cancer Therapies
(Insider Monkey) -15.00%
07:55AM
Lantern Pharma Unveils Innovative AI-Powered Module to Improve the Precision, Cost and Timelines of Antibody-Drug Conjugate (ADC) Development for Cancer
(Business Wire)
Jan-17-25 01:29PM
Lantern Pharma Inc. (LTRN): AI-Driven Cancer Drug Development
(Insider Monkey)
Dec-10-24 10:40AM
AI-Powered Cancer Solutions: Lantern Pharma (LTRN) Launches Phase 2 Trial in Taiwan
(Insider Monkey)
Dec-09-24 12:21PM
Lantern Pharma starts dosing in Taiwan in non-smoker lung cancer trial
(Clinical Trials Arena)
08:15AM
Lantern Pharma Announces First Patient Enrolled in Taiwan for Phase 2 HARMONIC Clinical Trial of LP-300 in Never-Smoker NSCLC Patients
(Business Wire)
Dec-07-24 01:59AM
Lantern Pharma Inc. (LTRN) Receives Second FDA Fast Track Designation for LP-184 in Triple Negative Breast Cancer
(Insider Monkey)
Dec-03-24 08:00AM
Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives Second Fast Track Designation from FDA for Treatment of Triple Negative Breast Cancer (TNBC)
(Business Wire)
Nov-26-24 08:45AM
Lantern Pharma and Starlight Therapeutics Present LP-184 (STAR-001) Phase 1b Trial Design and Preclinical Data in Glioblastoma at Society for Neuro-Oncology (SNO) 2024 Highlighting Novel Synthetic Lethality
(Business Wire)
Nov-19-24 08:00AM
Lantern Pharma Announces First Patient Dosed in Japan for The Expansion Cohort in The Phase 2 HARMONIC Clinical Trial of LP-300 in Never-Smoker NSCLC Patients
(Business Wire)
Nov-08-24 06:03PM
Lantern Pharma Inc (LTRN) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Rising ...
(GuruFocus.com) +12.28% -8.59%
Nov-07-24 04:05PM
Lantern Pharma Reports Third Quarter 2024 Financial Results and Business Updates
(Business Wire)
Nov-05-24 08:00AM
Starlight Therapeutics Announces Inaugural Members of Scientific Advisory Board
(Business Wire)
Oct-31-24 08:00AM
Lantern Pharma to Report Third Quarter 2024 Operating & Financial Results on November 7th, 2024 at 4:30 p.m. ET
(Business Wire)
Oct-23-24 08:45AM
Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 30, 2024
(Business Wire)
Oct-21-24 08:00AM
Lantern Pharma to Host & Participate in Two Public Webinars During October
(Business Wire)
Oct-15-24 09:07AM
Lantern Pharmas Investigational Drug-Candidate, LP-184, Receives Fast-Track Designation in Glioblastoma from the FDA
(Business Wire)
Oct-09-24 05:56PM
Lantern Pharma Inc (LTRN) Q2 2024 Earnings Call Highlights: Promising Clinical Trials and ...
(GuruFocus.com)
Sep-23-24 08:00AM
Lantern Pharma Announces Three U.S. FDA Rare Pediatric Disease Designations Granted to LP-184 in Multiple Ultra Rare Childrens Cancers
(Business Wire)
Aug-31-24 02:02PM
Lantern Pharma Inc. (LTRN): A Penny Stock That Will Make You a Millionaire
(Insider Monkey)
Aug-08-24 04:01PM
Lantern Pharma Reports Second Quarter 2024 Financial Results and Business Updates
(Business Wire) -7.68%
Aug-07-24 09:31AM
Lantern Pharma Highlights Promising Preclinical Results of LP-184's Synergy with Checkpoint Inhibitors & Sensitizing Tumors That are Non-Responsive to Anti-PD1 Therapy in Collaboration with MD Anderson at Immuno-Oncology Summit 2024
(Business Wire) +12.26%
Aug-05-24 08:00AM
Lantern Pharma Announces Positive Clinical Update from Ongoing Phase 2 HARMONIC Clinical Trial for Never Smokers with Advanced NSCLC, Including an 86% Clinical Benefit Rate in the Initial Patient Cohort
(Business Wire) -5.88%
Aug-01-24 08:00AM
Lantern Pharma to Report Second Quarter 2024 Operating & Financial Results on August 8th, 2024 at 4:30 p.m. ET
(Business Wire)
Jul-10-24 08:30AM
Lantern Pharma Achieves Key Milestone Towards Development of Molecular Diagnostic for use in Oncology Clinical Trials for Patient Selection and Stratification with Drug Candidate LP-184
(Business Wire)
Jun-12-24 07:30AM
Lantern Pharma Receives Certificate of Patent from Japanese Patent Office (JPO) for Composition of Matter Covering Drug Candidate LP-284
(Business Wire)
May-23-24 11:51AM
Pancreatic Cancer Battle Intensifies: Biotech Innovations Aim to Boost Survival Rates
(PR Newswire)
May-09-24 04:02PM
Lantern Pharma Reports First Quarter 2024 Financial Results and Business Highlights
(Business Wire) +5.09% -9.54%
May-06-24 06:41AM
Lantern Pharma and Oregon partner to develop cancer treatment
(Pharmaceutical Technology) +11.38%
04:37AM
Lantern Pharma, Oregon Therapeutics Partner to Develop AI-Driven Cancer Drug Collaboration
(MT Newswires)
03:00AM
Oregon Therapeutics & Lantern Pharma Launch Strategic AI Collaboration to Optimize Development of First-In-Class Drug Candidate XCE853 A Potent Inhibitor of Cancer Metabolism
(Business Wire)
May-02-24 07:30AM
Lantern Pharma to Report First Quarter 2024 Operating & Financial Results on May 9th, 2024 at 4:30 p.m. ET
(Business Wire)
May-01-24 06:00AM
3 Machine Learning Stocks with the Potential to Make You an Overnight Millionaire
(InvestorPlace) +5.69%
Apr-24-24 08:00AM
Lantern Pharma Launches "Webinar Wednesdays" Featuring World-Class Physician Scientists & Key Opinion Leaders Discussing Critical Areas of Oncology Drug Development
(Business Wire) -6.76%
Apr-22-24 08:12AM
Lantern Pharma Receives Regulatory Approval to Expand Harmonic Clinical Trial for Non-Small Cell Lung Cancer in Never-Smokers into Japan and Taiwan
(Business Wire) +7.12%
Apr-10-24 08:45AM
Software Segment of Global A.I. Healthcare Billion Dollar Market Expected to Have Fastest Growth
(PR Newswire)
Mar-20-24 09:00AM
Global A.I. Medical Diagnostics Market Poised To Reach $3.7 Billion By 2028
(GlobeNewswire) +17.49%
Mar-19-24 09:06AM
Lantern Pharma Inc. (NASDAQ:LTRN) Q4 2023 Earnings Call Transcript
(Insider Monkey) -24.80%
Mar-18-24 08:53PM
LTRN Stock Earnings: Lantern Pharma Beats EPS for Q4 2023
(InvestorPlace) +14.48%
05:32PM
Lantern Pharma Inc Reports Progress and Financials for FY 2023
(GuruFocus.com)
04:02PM
Lantern Pharma Reports Fourth Quarter & Fiscal Year 2023 Financial Results and Business Highlights
(Business Wire)
Mar-15-24 08:00AM
Lantern Pharma Announces Initial Patients Dosed in First-In-Human Clinical Trial for AI-Guided Drug-Candidate, LP-284
(Business Wire) +18.37%
Mar-11-24 07:30AM
Lantern Pharma to Report Fourth Quarter and Fiscal Year 2023 Operating & Financial Results on March 18th, 2024 at 4:30 p.m. ET
(Business Wire) -23.58%
Mar-07-24 06:17AM
11 Best Artificial Intelligence Stocks Under $20 According To Hedge Funds
(Insider Monkey) +21.13%
Mar-05-24 08:01AM
Lantern To Participate in H.C Wainwright & Co.s (HCW) 1st Annual Artificial Intelligence Based Drug Discovery & Development Virtual Conference
(Business Wire) +5.95%
Mar-04-24 08:01AM
Lantern Pharma's A.I. Platform, RADR, Surpasses 60 Billion Data Points Anticipates Reaching 100 Billion Data Points in 2024, Paving the Way for Enhanced Cancer Therapy Innovations and Expedited Development Timelines
(Business Wire) +9.40%
Feb-20-24 08:01AM
3 AI Powerhouses Predicted to Soar 500% in the Next Tech Boom
(InvestorPlace)
Feb-15-24 08:01AM
Lantern Pharma Advances Unique ADC (Antibody Drug Conjugate) Program Across Multiple Solid Tumor Cancers
(Business Wire)
Jan-17-24 07:30AM
Starlight Therapeutics, a Subsidiary of Lantern Pharma Focused on CNS & Brain Cancers, Announces Dr. Marc Chamberlain as Chief Medical Officer
(Business Wire)
Dec-13-23 08:05AM
The 3 Most Undervalued AI Penny Stocks to Buy in December
(InvestorPlace)
Nov-30-23 08:00AM
FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-284 in High-Grade B-cell Lymphomas (HGBL)
(Business Wire)
Nov-10-23 11:31AM
Lantern Pharma Inc. (NASDAQ:LTRN) Q3 2023 Earnings Call Transcript
(Insider Monkey) -11.53%
Nov-08-23 06:43PM
Lantern Pharma Inc (LTRN) Reports Q3 2023 Financial Results and Provides Operational Updates
(GuruFocus.com) +33.21%
04:01PM
Lantern Pharma Reports Third Quarter 2023 Financial Results and Operational Highlights
(Business Wire)
Nov-01-23 08:00AM
Lantern Pharma to Report Third Quarter 2023 Operating & Financial Results on November 8th, 2023 at 4:30 p.m. ET
(Business Wire)
Oct-24-23 04:03PM
The 7 Most Undervalued AI Penny Stocks to Buy: October 2023
(InvestorPlace)
Lantern Pharma, Inc. engages in the development of drugs through leveraging artificial intelligence, machine learning, and genomic data. Its portfolio includes LP-100, LP-300, and LP-184. The company was founded by Arun K. Asaithambi, Gregory T. Tobin, and Peter L. Nara on November 7, 2013 and is headquartered in Dallas, TX.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Fletcher Aaron G.L.10% OwnerJun 13 '25Sale3.0940,000123,60049,957Jun 13 07:57 PM
Kreis Leslie W.10% OwnerJun 13 '25Sale3.0940,000123,60049,957Jun 13 07:50 PM
Fletcher Aaron G.L.10% OwnerJun 12 '25Sale3.3860,647204,98751,860Jun 13 06:06 AM
Fletcher Aaron G.L.10% OwnerJun 11 '25Sale3.409503,23054,746Jun 13 06:06 AM
Fletcher Aaron G.L.10% OwnerJun 10 '25Sale3.40165454,791Jun 13 06:06 AM
Kreis Leslie W.10% OwnerJun 12 '25Sale3.3860,647204,98751,860Jun 13 06:01 AM
Kreis Leslie W.10% OwnerJun 11 '25Sale3.409503,23054,746Jun 13 06:01 AM
Kreis Leslie W.10% OwnerJun 10 '25Sale3.40165454,791Jun 13 06:01 AM
Fletcher Aaron G.L.10% OwnerMay 27 '25Sale3.0521,03764,16356,467May 29 09:55 PM
Fletcher Aaron G.L.10% OwnerMay 29 '25Sale3.0320,20061,20654,792May 29 09:55 PM
Fletcher Aaron G.L.10% OwnerMay 28 '25Sale2.8715,00043,05055,753May 29 09:55 PM
Kreis Leslie W.10% OwnerMay 27 '25Sale3.0521,03764,16356,467May 29 09:53 PM
Kreis Leslie W.10% OwnerMay 29 '25Sale3.0320,20061,20654,792May 29 09:53 PM
Kreis Leslie W.10% OwnerMay 28 '25Sale2.8715,00043,05055,753May 29 09:53 PM
Bios Fund II, LPAffiliate (10% owner)May 27 '25Proposed Sale3.2953,454175,864May 27 09:00 PM
Bios Fund I QP, LPAffiliate (10% owner)May 27 '25Proposed Sale3.2929,57697,305May 27 08:58 PM
Bios Fund II NT, LPAffiliate (10% owner)May 27 '25Proposed Sale3.2925,84985,033May 27 08:56 PM
Bios Fund I, LPAffiliate (10% owner)May 27 '25Proposed Sale3.2975,941249,846May 27 08:55 PM
Bios Fund II QP, LPAffiliate (10% owner)May 27 '25Proposed Sale3.29105,180346,042May 27 08:53 PM
open in screener | open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)